ours, have reported that IL-6 − / − mice develop increased fat mass from approximately 6 months of age. 7, 8, 10 This fat mobilising action of IL-6 in mice and rats may be exerted at the level of the central nervous system (CNS), probably the hypothalamus and/or the brainstem. 6, 10 A lack of IL-6 could dampen the anti-obesity effect of leptin, whereas brainspecific overproduction of IL-6 may enhance the effect of leptin. 11, 12 The results of earlier studies indicate that the obesity reducing action of IL-6 is primarily exerted in the brain. 6, 10, 12, 13 Therefore, it could be of value to identify cells that contain interleukin-6 receptorα (IL-6Rα) and determine whether these cells are located in regions that influence food intake and energy balance. Earlier studies have indicated that IL-6Rα is present on neurons in arcuate nucleus (ARC), paraventricular nucleus (PVN) and lateral hypothalamic area (LHA) of the hypothalamus, as well as the nucleus of the solitary tract (NTS) in the hindbrain. [14] [15] [16] [17] Intracerebroventricular administration of IL-6 to experimental animals decreases body fat and increases energy expenditure and thermogenesis, 6, 10, 18, 19 whereas systemic administration of IL-6 is less effective. 6, 10 Moreover, IL-6 levels in the cerebrospinal fluid (CSF) of humans has been reported to be inversely correlated with body fat mass. 20 Taken together, these studies are in agreement with the assumption that exogenous and endogenous IL-6 in the ventricle system can play a role in metabolic regulation. If this is the case, one obvious and logical mechanism for how ventricle IL-6 could influence energy-regulating nuclei could be to target ventricle-lining cells.
Tanycytes are hypothalamic radial glia-like cells lining the ventricle walls, especially at the bottom of the third ventricle (3V). 21 This cell type has recently been implicated in the regulation of feeding and energy balance. [22] [23] [24] In the present study, we investigated whether IL-6Rα is located in tanycytes. To demonstrate that immunoreactive IL-6Rα were responsive to IL-6, we injected IL-6 i.c.v. or i.p. and then investigated whether IL-6 induced phosphorylated signal transducer and activator of transcription-3 (pSTAT3) immunoreactivity in tanycytes. We also measured pSTAT3-immunoreactivity in the ARC, an area previously found to contain IL-6Rα. 16 For comparison we measured immunoreactive pSTAT3 after i.c.v. or i.p. administration of leptin, a well-known inducer of pSTAT3 in tanycytes and ARC. 23 
| MATERIALS AND METHODS

| Animals
C57BL6 male and female wild-type mice, aged 4-6 months of age (Jackson Laboratories, Bar Harbor, ME, USA), were used for the immunohistochemical staining. Animals had free access to water and standard chow pellets (Tekland Global, Harlan, the Netherlands) and were kept under a 12:12 hours light/dark cycle (lights on 06.00 hours), 50%-60% relative humidity at 24-26°C temperature. All animal procedures were approved by the local ethics committee for animal care at the University of Gothenburg, and were conducted in accordance with their guidelines.
| Tissue preparation for immunohistochemistry
Mice were anaesthetised with a rompun-ketamine mixture and perfused transcardially with heparinised saline (50 IU mL -1 ) followed by 4% paraformaldehyde in 0.1 mol L -1 phosphate buffer. The brains were removed and post-fixed in 4% paraformaldehyde in 0.1 mol L -1 phosphate buffer containing 15% sucrose overnight at 4°C. They were then transferred to a 30% sucrose solution in 0.1 mol L -1 phosphate buffer until sectioning.
Coronal sections (thickness 20 μm) of the hypothalamus (Bregma −1.70 to −1.94, interneural 2.10 to 1.86) were cut using a CM3050S cryostat (Leica Microsystem, Wetzlar, Germany) and stored in tissue storage solution (25% ethylene glycol, 25% glycerol, 50% 0.1 mol L -1 phosphate buffer).
| Immunohistochemistry
Sections were rinsed in Tris-NaCl-Triton-X (TNT) washing buffer (0.1 mol L -1 TrisHCl, pH 7.5, 0.15 mol L -1 NaCl, 0.2% Triton-X-100) and then blocked for 1 hour with Tris-NaCl-blocking buffer (TNB) (Perkin Elmer, Waltham, MA, USA). Sections were then incubated with primary antibodies against IL-6Rα along with either antibodies against dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), vimentin, glial fibrillary acidic protein (GFAP), pSTAT3 or glucose transporter-1 (GLUT-1) ( Sections were incubated with secondary antibodies only, or with mismatching primary and secondary antibodies, resulting in negative staining as a control for unwanted cross-reactivity. To confirm the identification of tanycytes, two different antibodies were used; DARPP-32 25, 26 and vimentin ( Table 1) . As a control for the IL-6Rα-antibody against the extracellular domain used in the main study, a second IL-6Rα-antibody against the intracellular domain was used as a control (see Supporting information, Figure S1 ).
| Confocal microscopy and cell counting
Images of the stained sections were obtained using either a confocal microscope system (LSM 700; Carl Zeiss, Oberkochen, Germany), together with a Plan APO ×63 A/1.40 oil lens (for close-up images) or a Plan Fluor ×20/0.75 lens (for anatomical overview pictures) and a solid-state laser. Images for each stain were taken in series with the same exposure times and light settings for each slide. The pinhole was set to 1 airy unit. Images were then processed using fiji software (http://fiji.sc/Fiji) using the same settings for contrast and brightness for all slides. Brain sections were then averaged for each animal and representative images chosen for cell counting. For i.p. injection, mice were injected with 100 μL of recombinant rat IL-6 (80 ng per mouse; PeproTech) or recombinant murine leptin (3 mg kg -1 ; PeproTech) in sterile NaCl or NaCl only. To confirm that i.p. administration of IL-6 was successful, we measured pSTAT3immunoreactivity in the subfornical organ, a part of the brain outside the blood-brain barrier, as a positive control (see Supporting information, Figure S3 ). NaCl administration was used as a negative control and resulted in the absence of pSTAT3-immunoreactivity (not shown).
The dose of IL-6 given i.p. was chosen from previous studies and is intended to be physiological rather than pathophysiological. The dose of IL-6 with respect to body weight given i.p. as reported by Wallenius et al., 10 and resulted in serum IL-6 levels much lower than those observed after after lipopolysaccharide treatment.
Mice were anaesthetised with domitor-ketamine and perfused as above 15 minutes after injection. Injection doses of IL-6 i.c.v., 6 leptin i.c.v., 27 leptin i.p. 23 and IL-6 i.p. 10 were selected in accordance with previous studies. Figure 1A -D shows that vimentin immunoreactive cells (in red) have a characteristic distribution along the 3V wall. These cells aggregate towards the basal parts of the ventricle wall with a few spread cells along the lateral walls ( Figure 1A ). This is in good agreement with the distribution reported for β-tanycytes 21 and vimentin has previously been used as a marker for tanycytes. 28 
| RESULTS
| IL-6Rα-immunoreactivity is located in vimentinor DARPP-32-immunoreactive cells lining the floor and ventral walls of the 3V
| IL-6Rα-immunoreactivity is present, to a lesser degree, on GLUT-1-immunoreactive ependymal cells at the lateral wall of the 3V
Co-staining of IL-6Rα with GLUT-1 (used here as a marker of ependymal cells of the blood-brain barrier) ( Figure 2 ) showed a different pattern from the vimentin-or DARPP-32-immunoreactivity ( Figure 1 ). Some of the GLUT-1-immunoreactive cells (red) in the lateral wall of the 3V also showed IL-6Rα immunoreactivity (green) ( Figure 2C , red arrowheads). By contrast, cells at the ventral part of the 3V lateral wall showed only IL-6Rα-immunoreactivity without GLUT-1-immunoractivity ( Figure 2C , white arrowheads).
Indeed, cell counting showed that approximately 35% of the GLUT-1-immunoreactive cells also showed IL-6Rα-immunoreactivity ( Figure 1H ). Taken together, these results indicate that the IL-6Rα
is mainly located in vimentin-or DARPP-32-immunoreactive 3V lining cells, presumably tanycytes, bordering the median eminence and ARC. This differs from the sparse IL-6Rα-immunoreactivity observed in GLUT-1-immunoreactive cells. Cell counting shows that approximately 52% and 49% of the vimentin-immunoreactive cells also showed pSTAT3-immunoreactivity in mice treated with i.c.v. IL-6 and leptin, respectively ( Figure 4A ).
| IL-6 or leptin induced pSTAT3immunoreactivity 5 minute after i.c.v. injection in ventricle lining vimentin-immunoreactive cells
Approximately 43% or 35% of the cells in the ARC were positive for pSTAT3 in mice treated with i.c.v. IL-6 and leptin, respectively ( Figure 4A ). 
| Intracerebroventicular administered IL-6 or leptin induced pSTAT3-immunoreactivity in ARC cells 15 minute after injection
| Intraperitoneal administration of leptin, but not IL-6, increased pSTAT3-immunoreactivity in the ARC after 15 minute
| DISCUSSION
The results of the present study indicate that functional ligand binding IL-6Rα are located in ventricle lining cells of the 3V in mice, especially on β-tanycytes at the bottom of the 3V. This group of tanycytes lies close to the ME and ARC and has recently been shown to be of importance for energy balance and metabolism. 23 Tanycytes in the lateral 3V wall are interspersed with ependymal cells that show GLUT-1immunoreactivity. 30 In the present study, IL-6Rα-immunoreactivity in GLUT1 positive ependymal cells was scarce in comparison with tanycytes. Intracerebroventricular injection of IL-6 increased STAT3 phosphorylation, a well-known intracellular mediator step in IL-6 signalling, 31 in tanycytes after 5 minutes. The latter finding indicates that the IL-6Rα on tanycytes are functional.
There is a growing body of evidence that IL-6 can decrease body fat mass via effects in the brain. Previous studies have shown that deficiency of IL-6 is causing mature onset obesity, 7, 8, 10 
anti-obesity effect is exerted at the level of the brain. 6, 20, 32 In addition, there is evidence that brain IL-6 is crucial in the anti-obesity signalling of both GLP-1 analogues and amylin analogues. [33] [34] [35] [36] These functions of IL-6 are of clinical relevance, given that both GLP-1-and amylin analogues are widely used for treatment of diabetes and obesity. 37, 38 Tanycytes appear to be very versatile cells and express a range of receptors for endocrine and paracrine signals (eg, GPR50, TSH-R, FGFR1 and NMU-R). More specifically, tanycytes are important in the regulation of body fat mass and leptin responsiveness. [21] [22] [23] 39 Tanycytes could be the initial target cells for anti-obesity effect exerted in the brain by leptin, a peptide released from fat tissue in relation to fat mass that may reach tanycytes via the blood, as suggested previously. 23 IL-6 produced in the brain may exert a similar anti-obesity effect after reaching its receptor on tanycytes via the CSF. The leptin receptor shares similarities with class 1-cytokine receptors, such as IL-6Rα, utilising the same Janus kinase-STAT signalling pathway, and the ligands leptin and IL-6 are also related chemically. 31 It remains to be investigated whether CSF IL-6 and blood leptin can potentiate each other's effects on tanycytes.
IL-6 injected systemically, which could be assumed to only reach tanycytes via the blood circulation from the median eminence, did not induce an increase in pSTAT3-immunoreactivity in these cells.
As expected and in agreement with earlier studies, 23 leptin induced pSTAT3 in the ARC both when given systemically and i.c.v. STAT3 is a well-known mediator of the biological effects of IL-6. 31, 40 Therefore, it is possible that ventricular but not systemic IL-6 plays a role in regulating biological functions of tanycytes. Further investigations would be required to determine the precise location of IL-6Rα on tanycytes.
In relation to our present findings of functional IL-6Rα, metabolically active tanycytes, it is of interest that i.c.v. administration of IL-6 was found to decrease body fat mass, increase energy expenditure and thermogenesis in mice. 6, 10, 12, 19, 41 No such effect was observed after systemic administration of IL-6 at a similar 6 or much higher (Wallenius V, Wallenius K, Feldt J, Wernstedt I, Jansson JO, unpublished observation) dose.
In the present study, we used two different markers for tanycytes:
DARPP-32 and vimentin. At the bottom of 3V, we found extensive and similar immunoreactivity with both markers, a finding that is in agreement with the well-known presence of tanycytes in this area. 22 Vimentin is an intermediate filament protein that is expressed in mesenchymal cells. In addition, vimentin binds to smooth muscle cells lining capillaries. DARPP-32, on the other hand, binds to a dopamine intracellular second messenger protein, which is found in tanycytes.
The DARPP-32 antiserum appears to be more specific for tanycytes, whereas vimentin stains a wider range of cells. 25, 26, 42 In the present study, the immunoreactivity pattern of the two antibodies was very similar at the bottom of the 3V. This led us to conclude that both antibodies stain tanycytes in this area and we mainly used vimentin as a tanycyte marker in our study.
In the present study, we found that some cells below the ventricular lining cells at the bottom of the third ventricle were positive for the astrocyte marker GFAP and also positive for IL-6Rα (see Supporting information, Figure S2 ). This is in contrast to previous data from other parts of the hypothalamus (eg, the PVN, 14 
and ARC 16 ), as well as the NTS of the hindbrain 43 where no such co-localisation between GFAP and IL-6Rα was found. However, astrocytes are a diverse group of cells and the astrocytes in the subventricular area of the 3V have been reported to differ from other astrocytes. Instead, the subventricular astrocytes may have similarities to tanycytes, such as being positive for DARPP-32 25 and IL-6Rα (present study).
As discussed above, the results of the present study indicate that there are functional IL-6Rα in cell membranes of mouse tanycytes.
Timper et al. 44 recently reported that i.c.v. administration of IL-6 can exert biological effects in the absence of IL-6Rα located in neurones of the hypothalamus. These effects were proposed to be exerted via so called trans-signalling, a phenomenon that has also been studied extensively elsewhere. [45] [46] [47] In the present study, i.c.v. injection of IL-6 caused a short-term increase in pSTAT3 in tanycytes, as observed at 5 but not 15 minutes. Timper et al. 44 found that i.c.v. IL-6 treatment suppressed food intake, whereas our group has reported increased energy expenditure and decreased body fat mass after i.c.v. IL-6 injection. 6, 10 Moreover, there are several other differences between our experimental protocol and that of Timper et al., 44 including IL-6 dose, target cell type, diet and type of vehicle. For example, the dose of IL-6 given i.p. by Timper et al. 44 was considerably higher (400 ng per mouse) than the dose given by us (80 ng per mouse). This may explain why we did not observe an effect of i.p. IL-6 treatment. However, the dose of IL-6 given i.p. in the present study was sufficiently high to induce pSTAT3 staining in some parts of the brain (see Supporting information, Figure S3 )
It appears likely that a substantial part of all IL-6 effects are exerted via integral IL-6Rα, at least in mice fed normal chow. This would be in agreement with the current paradigm for how hormones in general are acting on cells via cell membrane receptors. 48 However, further studies are needed to investigate to what extent the effects on tanycytes by IL-6 are exerted via membrane bound receptors or via trans-signalling.
There is confirmation that not only the IL-6Rα, but also the IL-6 ligand is produced locally in the CNS. We were able to measure substantial IL-6 mRNA levels in the hypothalamus of animals without inflammation as shown previously. 32 The levels of IL-6 mRNA in the CNS appear to be regulated (eg, by GLP-1 and amylin), 32, 35 further supporting the idea of IL-6 production being of physiological relevance.
The fact that IL-6 levels are higher in CSF than in serum in many humans further argues for the local production of IL-6 in the CNS. 20 So far, it has been difficult to determine exactly in which cells and parts of the hypothalamus that IL6 is produced during health, partly as a result of lack of verified specific IL-6 antibodies that can used for immunohistochemistry. The results of studies using other techniques suggest that IL-6 can be produced by microglia or astrocytes in vitro, although this may not reflect the situation in vivo. 35, 49 In summary, less in known about the localisation of the IL-6 ligand compared to IL-6Rα in healthy animals.
In summary, the results of the present study show that the ligand binding part of the IL-6 receptor, IL-6Rα, is present on β-tanycytes at the bottom of the 3V. These cells have been reported as being of importance in the regulation of energy balance and body fat mass and, recently, they were hypothesised to be a frontline target cell for the metabolic effects of leptin. 39 Tanycytes show pSTAT3-immunoreactivity, similar to leptin, after i.c.v., but not i.p., administration of IL-6, indicating that IL-6 produced locally in the brain could be of importance for these cells. This lends new support to our hypothesis that locally produced IL-6 in the brain plays an important role in the regulation of metabolism.
